reports
Kerecis included on the list of covered products for Diabetic Foot Ulc...
Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision al...
Coloplast A/S - Indkaldelse til ordinær generalforsamling 2024
Coloplast A/S - Indkaldelse til ordinær generalforsamling 2024 Den ordinære generalforsamling i Coloplast A/S afholdestorsdag den 5. december 2024 kl. 15:30på Coloplast A/S’ adresse, Holtedam 3 (Aage Louis-Hansen Auditorium), Humlebæk, Danmark.Indkaldelsen til den ordinære generalforsamling er vedlagt. For yderligere information, kontakt venligstInvestorer og analytikere Anders Lonning-SkovgaardExecutive Vice President, CFO Tlf. 4911 1111 Aleksandra Dimovska Vice President, Investor Relations Tlf. 4911 1800 / 4911 2458 E-mail: Presse og medier Peter Mønster Sr. Media Relations...
Coloplast A/S - Notice of Annual General Meeting 2024
Coloplast A/S - Notice of Annual General Meeting 2024 The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark.The notice of the Annual General Meeting is enclosed. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. Aleksandra Dimovska Vice President, Investor Relations Tel. / Email: Press and media Peter Mønster Sr. Media Relations Manager Tel....
- Roy Külter
- Steven Boumans
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/06/2024
Our baseline scenario materialised last night: Donald Trump seems to be on course to win the US presidential election, and the choice of the electorate is unlikely to be challenged. He could end up with a majority in both houses of Congress. US equities will be the first to benefit from this development. In European equities, the biggest winners will be Energy, Media, Metals, Construction & Materials, Financial Services and Insurance. More at risk, however, are the Utilities, Spirits,...
AKE ARKEMA
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
UBSN UBS GROUP AG
PUM PUMA SE
EN BOUYGUES SA
VNA VONOVIA SE
ORSTED ORSTED
FRE FRESENIUS SE & CO. KGAA
NEX NEXANS SA
HEN3 HENKEL AG & CO. KGAA PREF
EDW EDP RENOVAVEIS SA
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
COLO B COLOPLAST A/S CLASS B
RACE FERRARI NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
VOD VODAFONE GROUP PLC
SHL SIEMENS HEALTHINEERS AG
NEOEN NEOEN S.A.
VWS VESTAS WIND SYSTEMS
CTPNV CTP NV
NOVO B NOVO NORDISK A/S
UN0 UNIPER SE
- Roy Külter
- Steven Boumans
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 06/11/2024
Notre scénario central s’est concrétisé dans la nuit : Donald Trump remporte la présidentielle américaine, et le choix des électeurs ne devrait pas être contesté. Il pourrait disposer d’une majorité dans les deux assemblées. Les actions américaines en seront les premières bénéficiaires. Sur les actions européennes, les secteurs les plus gagnants seront l’Energie, les Médias, les Métaux, Construction & Materials, Financial Services, Insurance. Sont en revanche plus à risque Utilities, ...
AKE ARKEMA
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
UBSN UBS GROUP AG
PUM PUMA SE
EN BOUYGUES SA
VNA VONOVIA SE
ORSTED ORSTED
FRE FRESENIUS SE & CO. KGAA
NEX NEXANS SA
HEN3 HENKEL AG & CO. KGAA PREF
EDW EDP RENOVAVEIS SA
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
COLO B COLOPLAST A/S CLASS B
RACE FERRARI NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
VOD VODAFONE GROUP PLC
SHL SIEMENS HEALTHINEERS AG
NEOEN NEOEN S.A.
VWS VESTAS WIND SYSTEMS
CTPNV CTP NV
NOVO B NOVO NORDISK A/S
UN0 UNIPER SE
- Oliver Metzger
Coloplast : FY review – Incorporating some cost headwinds for 2025
>Q4 review – Slight beat on top and bottom line - Coloplast’s Q4 2024 revenues were slightly ahead of expectations driven by a better-than-expected performance at Continence care (10% organic growth) and at Voice & Respiratory care (12% organic growth). On the bottom line, the company achieved an adj. EBIT 2% ahead of expectations. Guidance incorporates some cost headwinds - For 2025, Coloplast expects organic growth of around 8-9% with a neutral fore...
- ABGSC Healthcare Research
- Morten Larsen
- Rune Majlund Dahl
Coloplast (Hold, TP: DKK930.00) - EBIT margin uncertainty persists
Coloplast missed its guidance for full-year organic growth, but met the low end for the EBIT margin before special items. The 2024/25 guidance is for 8–9% organic growth and a c28% EBIT margin (consensus 28.4%). Returning to the 30%+ guided beyond Strive25 hinges on external factors. We assume the inclusion of Kerecis in the LCD policy (decision due at end-2024e), and reiterate our BUY, but have cut our target price to DKK930 (950).
- Damien Choplain
- Martial Descoutures
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/05/2024
European equity markets weakened in October following multiple disappointments across the earnings season. The impending US election, the outcome of which is highly uncertain according to the polls, may also have prompted some traders to adopt a cautious stance. Sovereign long rates rose sharply, particularly in the US, on the back of macro indicators likely to provide arguments to the most hawkish of central bankers. All eyes are now on the November 5 elections and their repercussion...
- Damien Choplain
- Martial Descoutures
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 05/11/2024
Les marchés actions européens ont fléchi en octobre après les nombreuses déceptions sur la saison des résultats. L’approche de l’élection US, très incertaine selon les sondages, pourrait également avoir poussé à la prudence certains opérateurs. Les taux longs souverains ont nettement remonté, en particulier aux Etats-Unis, sur la base d’indicateurs macro susceptibles de donner des arguments aux plus faucons des banquiers centraux. Tous les yeux sont désormais rivés sur le scrutin du 5...
- Oliver Metzger
Coloplast : Q4 review – Good quarter, bottom line guidance implies sli...
>Q4 review – Slight beat on top and bottom line - Coloplast’s Q4 2024 revenues of DKK 6,983m (+11.7% y-o-y) were 0%/1% vs ODDO BHF/consensus, driven by organic growth of 8% (7.7%/8.0% vs ODDO BHF/consensus). External growth contributed to the tune of 4% and forex created a headwind of 100bp. Coloplast achieved an adj. EBIT of DKK 1,913m (+16.3% y-o-y, margin 27.5%), which was 2%/2% vs expectations. EPS of DKK 5.83 compares to our DKK 6.52 and consensus’ DKK 6.00....
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Årsrapport 2023/24 & Vederlagsrapport 2023/24
Coloplast A/S - Årsrapport 2023/24 & Vederlagsrapport 2023/24 Coloplast A/S - Årsrapport 2023/24 & Vederlagsrapport 2023/24 Organisk vækst på 8% og en overskudsgrad1 på 27% for regnskabsåret 2023/24. Den rapporterede omsætning målt i danske kroner steg 10% til 27.030 mio. kr. Den organiske vækst pr. forretningsområde var 7% i Stomi, 8% i Kontinens, 11% i Stemme og Respiratorisk Pleje, 10% i Avanceret Sårpleje (8% i Avancerede Sårbandager) og 5% i Urologi. Kerecis bidrog med 4 procentpoint til den rapporterede vækst med en underliggende vækst på ca. 35%...
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 11%, Advanced Wound Care 10% (Advanced Wound Dressings 8%) and Interventional Urology 5%. Kerecis contributed 4%-points to reported growth, with an underlying growth of around 35%, in line with expectations. EBIT1 was DKK 7,286 million, a...
Coloplast A/S - Årsregnskabsmeddelelse 2023/24
Coloplast A/S - Årsregnskabsmeddelelse 2023/24 2023/24 Årsregnskabsmeddelelse 1. oktober 2023 – 30. september 2024 Coloplast leverede organisk vækst på 8% og en overskudsgrad1 på 26% i 4. kvartal, negativt påvirket af ekstraordinære omkostninger og valutaudvikling. Den rapporterede omsætning målt i danske kroner steg 12% med et bidrag på 3 procentpoint fra Kerecis-opkøbet (2 måneders effekt). Den organiske vækst pr. forretningsområde var 6% i Stomi, 10% i Kontinens, 12% i Stemme og Respiratorisk Pleje, 10% i Avanceret Sårpleje (4% i Avancerede Sårbandager) og 7% i Urologi...
Coloplast A/S - Full-Year Financial Results 2023/24
Coloplast A/S - Full-Year Financial Results 2023/24 2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution from the Kerecis acquisition (two months). Organic growth rates by business area: Ostomy Care 6%, Continence Care 10%, Voice and Respiratory Care 12%, Advanced Wound Care 10% (Advanced Wound Dressings 4%) and Interventional Urology 7%.Growth in Chron...
Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive...
Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive Leadership Team Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect. “We have entered the final year of our 2025 strategy. In this strategic period, Coloplast has made significant investments to expand the reach of the company and build four growth platforms, Chronic Care, Voice & Respiratory Care, Advanced Wound Care and Interventional Urology, which must drive value creation in the years t...
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conferenc...
Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts.A presentation will be available on Coloplast's website approximately 1 hour before the conference call.Please note that the webcast of the conference call will be available during and after the event. Coloplast will b...
- Rune Majlund Dahl
Coloplast (Hold, TP: DKK950.00) - Focus on the 2024/25 guidance
We expect Coloplast to reach its 2023/24 guidance, with Q4 organic revenue growth of 8.0% driven by the Chronic Care segment, and an EBIT margin before special items of 27.6% (consensus 27.5%). We look for 2024/25 guidance of 8–9% organic revenue growth and a 28–29% EBIT margin. The LCD policy decision is due at end-2024 (we assume the inclusion of Kerecis). We reiterate our HOLD, but have cut our target price to DKK950 (1,000).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.